Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-enriched Rheumatoid Arthritis Patients.

Christina Charles-SchoemanRoy M FleischmannEduardo MyslerMaria GreenwaldSteven R YtterbergGary G KochDeepak L BhattCunshan WangTed R MikulsAll-Shine ChenCarol A ConnellJohn C WoolcottSujatha MenonYan ChenKristen LeeZoltán Szekanecz

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

Incidences of VTE and PE were higher with tofacitinib (10>5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, BMI, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.

Keyphrases

venous thromboembolism
rheumatoid arthritis
disease activity
rheumatoid arthritis patients
risk factors
direct oral anticoagulants
ankylosing spondylitis
interstitial lung disease
ulcerative colitis
body mass index
big data
artificial intelligence
idiopathic pulmonary fibrosis
case control